

Colgate Palmolive Co. (CL)

NYSE; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0000021665

Colgate Palmolive Co. CL; chemicals	
Grade	A ▼ A B C D E strongest fifth of 331 graded peers percentile 13.9; sampling error 2.7 points; lower is stronger
Rank	41 of 331
Profitability	A ■ percentile 9.7
Solvency	C ■ percentile 52.9
Growth and financing	C ■ percentile 48.0
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$16.3B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	12 of 14
Graded from	filings received through Feb 23, 2026 228 days before the rescans; latest periodic filing 10-Q received Jul 31, 2026
Last close	\$88.12 2026-10-08; market equity \$70.2B
Price used in grade	None




A, the bull

strongest fifth of its sector;
letters are fifths of the 331
graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Feb 21, 2023, B from Nov 21, 2023, A/B from Feb 21, 2025, A from Mar 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 23, 2026

Colgate-Palmolive Company (together with its subsidiaries, "we," "us," "our," the "Company" or "Colgate-Palmolive") is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. To achieve our business and financial objectives and deliver peer-leading performance and total shareholder return, we are focused on driving organic sales growth; delivering consistent, compounded earnings per share growth; achieving operational efficiencies; and

driving growth in free cash flow along with the efficient use of our balance sheet.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 9.7						
Gross profitability		75.0%	21.3%	1.4	359	2025-12-31
Return on invested capital		38.4%	9.5%	4.1	124	2025-12-31
Accruals ratio		(12.8%)	(4.2%)	15.8	400	2025-12-31
Gross margin stability, five years		1.3 pts	2.2 pts	17.7	301	2025-12-31
Solvency, sleeve percentile 52.9						
Twelve-month failure probability		not computable	0.05%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		6.21	3.41	19.7	301	2025-12-31
Net debt to EBITDA		1.66x	1.88x	44.3	150	2025-12-31
Interest coverage		not computable	4.16x			one or more required annual facts are missing
Current ratio		0.83x	2.20x	94.8	423	2025-12-31
Growth and financing, sleeve percentile 48.0						
Revenue growth, three-year compound		4.3%	1.2%	35.2	350	2025-12-31
Free cash flow growth, three-year compound		25.0%	12.6%	33.1	179	2025-12-31
Reinvestment rate		(31.4%)	24.3%	81.7	170	2025-12-31
Asset growth, three years		1.3%	2.9%	60.1	369	2025-12-31
Net share issuance, one year		(1.2%)	0.0%	30.0	321	2026-01-31

Among 331 peers

chemicals; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
36	Enerpac Tool Group Corp. (EPAC)	12.2	A	
37	Compex International Inc. (CIX)	12.6	A	fortress balance sheet
38	Acme United Corp. (ACU)	13.0	A	
39	Cummins Inc. (CMI)	13.4	A	
40	Weatherford International plc (WFRD)	13.8	A	
41	Colgate Palmolive Co. (CL) <	13.9	A	
42	Lennox International Inc. (LIH)	14.2	A	
43	Innospec Inc. (IOSP)	14.2	A	fortress balance sheet

44	Newmarket Corp. (NEU)	14.5	A
45	Park Aerospace Corp. (PKE)	14.6	A late filer, fortress balance sheet
46	Kadant Inc. (KAI)	15.0	A

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	15.2%	13.8%	51
Distance from 52-week high	(11.1%)	(24.2%)	82
EBIT to enterprise value	4.3%	3.9%	55
Free cash flow yield	5.2%	3.2%	70
Book value to price	0.00	0.39	4
Sales to price	0.29	0.57	26
Composite equity issuance, five years	(19.3%)	(9.9%)	24
Relative strength against the sector, log excess return	(0.03)	(0.02)	48

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$1.4B
Operating cash flow, four quarters	\$4.5B
Months of runway	not finite
Days since last periodic filing	70 (10-Q received Jul 31, 2026)
Median daily dollar volume, 63 sessions	\$389.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$12.3B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
2	assets	us-gaap:Assets	\$16.3B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
3	operating income	us-gaap:OperatingIncomeLoss	\$3.3B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$5.1B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$798.0M	2025-12-31	2026-02-23	10-K	0000021665-26-000006
6	total debt	us-gaap:LongTermDebt	\$7.8B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
7	book equity	us-gaap:StockholdersEquity	\$54.0M	2025-12-31	2026-02-23	10-K	0000021665-26-000006
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.3B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
9	total debt	us-gaap:LongTermDebt	\$7.0B	2024-12-31	2025-02-13	10-K	0000021665-25-000008
10	book equity	us-gaap:StockholdersEquity	\$212.0M	2024-12-31	2026-02-23	10-K	0000021665-26-000006
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.1B	2024-12-31	2026-02-23	10-K	0000021665-26-000006
12	net income	us-gaap:NetIncomeLoss	\$2.1B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$4.2B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
14	assets	us-gaap:Assets	\$16.0B	2024-12-31	2026-02-23	10-K	0000021665-26-000006
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$20.4B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
16	gross profit	us-gaap:GrossProfit	\$12.2B	2024-12-31	2026-02-23	10-K	0000021665-26-000006
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$20.1B	2024-12-31	2026-02-23	10-K	0000021665-26-000006

18	gross profit	us-gaap:GrossProfit	\$11.3B	2023-12-31	2026-02-23	10-K	0000021665-26-000006
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$19.5B	2023-12-31	2026-02-23	10-K	0000021665-26-000006
20	gross profit	us-gaap:GrossProfit	\$10.2B	2022-12-31	2025-02-13	10-K	0000021665-25-000008
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$18.0B	2022-12-31	2025-02-13	10-K	0000021665-25-000008
22	gross profit	us-gaap:GrossProfit	\$10.4B	2021-12-31	2024-02-15	10-K	0000021665-24-000003
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$17.4B	2021-12-31	2024-02-15	10-K	0000021665-24-000003
24	current assets	us-gaap:AssetsCurrent	\$5.7B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
25	current liabilities	us-gaap:LiabilitiesCurrent	\$6.9B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$26.6B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
27	liabilities	us-gaap:Liabilities	\$16.0B	2025-12-31	2026-02-23	10-K	0000021665-26-000006
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$630.0M	2025-12-31	2026-02-23	10-K	0000021665-26-000006
29	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$564.0M	2025-12-31	2026-02-23	10-K	0000021665-26-000006
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$4.1B	2024-12-31	2026-02-23	10-K	0000021665-26-000006
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$561.0M	2024-12-31	2026-02-23	10-K	0000021665-26-000006
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.7B	2023-12-31	2026-02-23	10-K	0000021665-26-000006
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$705.0M	2023-12-31	2026-02-23	10-K	0000021665-26-000006
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.6B	2022-12-31	2025-02-13	10-K	0000021665-25-000008
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$696.0M	2022-12-31	2023-02-16	10-K	0000021665-23-000007
36	current assets	us-gaap:AssetsCurrent	\$5.3B	2024-12-31	2026-02-23	10-K	0000021665-26-000006
37	current liabilities	us-gaap:LiabilitiesCurrent	\$5.8B	2024-12-31	2026-02-23	10-K	0000021665-26-000006
38	assets	us-gaap:Assets	\$16.4B	2023-12-31	2025-02-13	10-K	0000021665-25-000008
39	assets	us-gaap:Assets	\$15.7B	2022-12-31	2024-02-15	10-K	0000021665-24-000003
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	801,548,028	2026-01-31	2026-02-23	10-K	0000021665-26-000006
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	811,536,437	2025-01-31	2025-02-13	10-K	0000021665-25-000008